These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 37188510)
1. The Unique Genetic Mutation Characteristics Based on Large Panel Next-Generation Sequencing (NGS) Detection in Multiple Primary Lung Cancers (MPLC) Patients. Liang Z; Zeng G; Wan W; Deng B; Chen C; Li F; Lin G; Lin Y; Lin H; Mo G; Miao H Discov Med; 2023 Apr; 35(175):131-143. PubMed ID: 37188510 [TBL] [Abstract][Full Text] [Related]
2. Clinical and genetic characteristics of early-stage multiple primary and independent primary lung adenocarcinoma patients. Li P; Yang R; Wang D; Wang L; Wang S; Liu C; Li J; Li L; Liu C; Tong Y; Wang Y Asia Pac J Clin Oncol; 2022 Oct; 18(5):e420-e426. PubMed ID: 35098658 [TBL] [Abstract][Full Text] [Related]
3. Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer. Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S Anticancer Res; 2018 Oct; 38(10):5627-5634. PubMed ID: 30275180 [TBL] [Abstract][Full Text] [Related]
4. Construction of a reference material panel for detecting Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175 [TBL] [Abstract][Full Text] [Related]
5. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1. Liu J; Liu Y Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors. Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224 [TBL] [Abstract][Full Text] [Related]
8. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer. Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871 [TBL] [Abstract][Full Text] [Related]
9. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785 [TBL] [Abstract][Full Text] [Related]
11. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing. Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271 [TBL] [Abstract][Full Text] [Related]
12. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Malapelle U; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Savic S; Bihl M; Bubendorf L; Salto-Tellez M; de Biase D; Tallini G; Hwang DH; Sholl LM; Luthra R; Weynand B; Vander Borght S; Missiaglia E; Bongiovanni M; Stieber D; Vielh P; Schmitt F; Rappa A; Barberis M; Pepe F; Pisapia P; Serra N; Vigliar E; Bellevicine C; Fassan M; Rugge M; de Andrea CE; Lozano MD; Basolo F; Fontanini G; Nikiforov YE; Kamel-Reid S; da Cunha Santos G; Nikiforova MN; Roy-Chowdhuri S; Troncone G; Cancer Cytopathol; 2017 Aug; 125(8):615-626. PubMed ID: 28475299 [TBL] [Abstract][Full Text] [Related]
13. Clinical Application of Next-Generation Sequencing-Based Panel to Park C; Kim M; Kim MJ; Kim H; Ock CY; Keam B; Kim TM; Kim DW; Kim JI; Heo DS Mol Cancer Ther; 2020 Mar; 19(3):937-944. PubMed ID: 31826932 [TBL] [Abstract][Full Text] [Related]
14. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer. Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783 [TBL] [Abstract][Full Text] [Related]
15. Next-Generation Sequencing: A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases. Patel SB; Kadi W; Walts AE; Marchevsky AM; Pao A; Aguiluz A; Mudalige T; Liu Z; Deng N; Lopategui J J Mol Diagn; 2017 Nov; 19(6):870-880. PubMed ID: 28866070 [TBL] [Abstract][Full Text] [Related]
16. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas. Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436 [TBL] [Abstract][Full Text] [Related]
17. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Pisapia P; Malapelle U; Roma G; Saddar S; Zheng Q; Pepe F; Bruzzese D; Vigliar E; Bellevicine C; Luthra R; Nikiforov YE; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Bihl M; Savic S; Bubendorf L; de Biase D; Tallini G; Hwang DH; Sholl LM; Vander Borght S; Weynand B; Stieber D; Vielh P; Rappa A; Barberis M; Fassan M; Rugge M; De Andrea CE; Lozano MD; Lupi C; Fontanini G; Schmitt F; Dumur CI; Bisig B; Bongiovanni M; Merkelbach-Bruse S; Büttner R; Nikiforova MN; Roy-Chowdhuri S; Troncone G; Cancer Cytopathol; 2019 May; 127(5):285-296. PubMed ID: 31021538 [TBL] [Abstract][Full Text] [Related]
18. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations. Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917 [TBL] [Abstract][Full Text] [Related]
19. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718 [TBL] [Abstract][Full Text] [Related]
20. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]